Category: Market News

BSF Enterprise (LSE:BSFA) reported unaudited interim results for the six months ended 31 March 2026, highlighting continued progress across its lab-grown leather, regenerative medicine and cell therapy businesses. During the period, the group advanced its strategy of transitioning from research and development towards commercialisation and clinical execution, strengthening its position in tissue-engineered materials and advanced biotechnology.

Product development gathers momentum

Lab-Grown Leather expanded its portfolio with three product families and introduced T-Rex Leather, a luxury lab-grown material created using synthetic dinosaur DNA. The business also showcased a fully tanned hide and unveiled a designer handbag collaboration. Meanwhile, subsidiary 3D Bio-Tissues broadened its CytoBoost product range and secured a £500,000 supply and technical services agreement with South Korean cultivated meat company Seawith. Kerato also reached the halfway stage of development for its LiQD Cornea biosynthetic implant while continuing work on regulatory approvals and quality management systems.

Funding strengthens growth plans

BSF reported a net loss of £956,625 for the period, with the higher loss reflecting increased legal, collaboration and product development costs, alongside the absence of grant income. To strengthen its financial position, the company secured a £300,000 convertible loan note during the reporting period before raising a further £385,000 through a share placing shortly afterwards. Additional funding completed in June, including another equity placing and a £1 million convertible loan note, is expected to support operations and strategic growth initiatives through 2026 and 2027.

Commercial strategy continues to evolve

The latest developments highlight increasing commercial engagement, broader validation of the group’s technologies and growing interest from strategic partners. BSF continues to strengthen its position across the luxury biomaterials and cellular agriculture sectors, with high-profile product launches, an expanding partnership pipeline and additional funding supporting its long-term commercialisation strategy built around proprietary platforms and differentiated bio-based products.

Outlook

BSF’s outlook remains constrained by ongoing financial losses, negative cash flow and weak technical market indicators, with the shares continuing to trade below key moving averages. Valuation support also remains limited given the company’s loss-making position and the absence of a dividend.

More about BSF Enterprise PLC

BSF Enterprise PLC is a UK-listed biotechnology company focused on tissue-engineered materials and regenerative medicine through its wholly owned subsidiaries 3D Bio-Tissues, Kerato and Lab-Grown Leather. Its activities span bio-based materials, cell culture technologies, cultivated meat applications and medical devices, serving industries including luxury fashion, biopharmaceuticals and corneal transplantation.

Lab-Grown Leather develops scaffold-free leather alternatives using synthetic DNA technology, while 3D Bio-Tissues supplies cell culture enhancement products such as CytoBoost to biotechnology and cultivated meat companies. Kerato is developing LiQD Cornea, a biosynthetic hydrogel implant designed to treat corneal damage without relying on donor tissue, supported by regulatory and grant-funded development programmes.

The group’s strategy focuses on protecting intellectual property, expanding strategic partnerships and accelerating the transition from research into commercial deployment and clinical application. Through a combination of proprietary technologies and relatively low-dilution funding structures, BSF aims to establish a leading position in the cellular agriculture and advanced biomaterials markets.

GCP Infrastructure Investments (LSE:GCP) has completed the refinancing of a portfolio of ground-mounted solar photovoltaic assets, introducing approximately £40 million of senior debt to replace what had previously been a fully equity-funded investment. The refinancing, completed using valuations consistent with the company’s 31 March 2026 net asset value, results in a loan-to-enterprise value ratio of around 38% and is expected to release approximately £40 million in cash as part of GCP’s wider capital recycling strategy.

Asset sales support capital recycling strategy

Alongside the refinancing, GCP is progressing a series of infrastructure disposals, including the sale of an anaerobic digestion asset for around £3 million, two onshore wind projects valued at approximately £10 million and a supported social housing portfolio that is expected to repay about £47 million of outstanding loans. The proceeds will primarily be used to reduce the company’s credit facilities, while surplus capital may be allocated to share buybacks or new investment opportunities in line with its capital allocation policy. With the shares continuing to trade at a significant discount to net asset value, regular share repurchases could account for a meaningful proportion of daily trading activity.

Outlook

GCP’s outlook is supported by a conservative balance sheet, improving cash generation and constructive technical market signals. These strengths are partly offset by uneven revenue performance and a relatively demanding price-to-earnings valuation, although the company’s attractive dividend yield, ongoing share buyback programme and disciplined capital management provide additional support.

More about GCP Infrastructure Investments Ltd

GCP Infrastructure Investments Ltd is a FTSE 250-listed, closed-ended investment company focused on delivering long-term, inflation-linked returns through investments in UK infrastructure debt. The portfolio is concentrated on projects backed by public sector or availability-based revenue streams, with a strong emphasis on infrastructure that delivers positive environmental and social outcomes.

Venture Life (LSE:VLG) delivered revenue of £50.0 million for the 17 months to 31 May 2026, representing a 30.9% increase on the previous reporting period, while pro forma revenue grew 16.0%, driven primarily by higher sales volumes. The company’s Power Brands now generate more than 90% of total revenue, with products including Lift, Balance Activ and Earol recording strong performances following increased marketing investment, new product launches and renewed partnerships with international distributors. Adjusted EBITDA is expected to be in line with market expectations.

AI transformation underpins operational strategy

Venture Life is implementing a digital-first transformation programme centred on Microsoft Dynamics 365, using artificial intelligence to improve demand forecasting, promotional planning and stock-keeping unit management. The company expects the initiative to deliver measurable financial benefits within the next 12 months. Net cash declined to approximately £12.0 million following the acquisitions of FemiClear and CUROXEN, while adjusted free cash flow improved to around £5.9 million. Management believes the group’s balance sheet remains strong enough to support further investment in brand marketing, portfolio optimisation and earnings-accretive acquisitions across its core UK and US markets.

Outlook

Venture Life’s outlook is supported by improving profitability and a significantly strengthened balance sheet with very low debt levels. However, these positives are partly offset by the swing to negative operating and free cash flow during 2025, together with fluctuating revenue and margin performance. Technical indicators remain weak despite oversold conditions, while valuation remains difficult to assess because of the company’s negative price-to-earnings ratio and the absence of a stated dividend yield.

More about Venture Life

Venture Life Group PLC is a UK-listed consumer healthcare company specialising in the innovation, development and commercialisation of products across women’s intimate health, ear care, energy, glucose management and menopause support. Its portfolio of Power Brands includes Balance Activ, Lift, Glucogel, Earol, Health & Her and Health & Him, alongside a growing oncology support range featuring Gelclair and Pomi-T. The company continues to focus its commercial expansion on the UK and US markets.

Chariot (LSE:CHAR) reported its audited 2025 full-year results, marking a year of significant strategic progress as it broadened its upstream oil and gas portfolio while accelerating the growth of its renewable energy business across Africa. With energy security remaining a key global priority, the company is strengthening its position as a supplier of both conventional and low-carbon energy to support the continent’s expanding energy needs.

Upstream portfolio grows across Angola and Morocco

In its upstream business, Chariot increased its exposure to offshore Angolan oil production through assets producing around 40,000 barrels per day. Following completion of the Etu Energias transaction, the company expects to receive cash flow equivalent to approximately 4,000 barrels per day. Chariot also regained operatorship and a 75% working interest in the Lixus and Rissana licences in Morocco, while redesigning the Anchois gas project to reduce capital expenditure without compromising its planned production capacity of up to 105 million standard cubic feet per day. The group also continues to assess additional exploration and new venture opportunities, including acreage in Namibia’s Orange Basin.

Renewable energy business continues to scale

Renewable energy subsidiary Etana Energy is progressing rapidly, with 400 MW of wind and solar capacity currently under construction and a development pipeline exceeding 500 MW. The business has secured long-term power purchase agreements with major industrial customers and financing from leading development finance institutions. Elsewhere, Chariot has interests in 194 MW of wind projects under construction, is advancing solar developments for mining customers in Zambia, South Africa and Zimbabwe, and continues to develop its Project Nour green hydrogen and associated green iron initiatives in Mauritania.

Capital raise supports growth strategy

The company strengthened its financial position through a US$24.3 million placing and open offer completed in March 2026, providing additional funding for upstream expansion and renewable energy development. The board has also proposed a share consolidation designed to reduce the number of ordinary shares in issue and rebase the share price as part of its broader strategy to improve market perception and support future growth.

Outlook

Chariot’s outlook continues to reflect financial challenges and weak technical market indicators, although recent strategic developments, new partnerships and the continued expansion of its renewable energy portfolio provide opportunities for longer-term improvement. The company’s valuation remains under pressure as it continues to report losses.

More about Chariot Limited

Chariot Limited is an Africa-focused energy company with operations spanning upstream oil and gas and renewable power generation. Its hydrocarbon portfolio includes producing, development and exploration assets in Angola and Morocco, alongside new venture opportunities across Africa. Its renewable energy division develops, owns and trades electricity for industrial and mining customers while advancing green hydrogen projects in Mauritania.

Listed on AIM under the ticker CHAR, the company has built a diversified energy platform focused on delivering reliable, competitive and sustainable energy solutions. Through partnerships with major industry participants and development finance institutions, Chariot aims to expand its presence across Africa’s rapidly growing energy markets while supporting both energy security and the transition to lower-carbon power.

Rockhopper Exploration (LSE:RKH) continues to streamline its portfolio as it shifts its strategic focus toward the North Falkland Basin and works to complete its withdrawal from Italy. The company’s long-term strategy is centred on its Falkland Islands assets, including the Sea Lion development, as it moves away from its legacy Italian operations.

Italian disposal remains pending

The planned sale of Italian subsidiary Rockhopper Civita Limited to Zodiac Energy has been delayed after Italian regulatory approval remained outstanding as of 30 June 2026. Although the Falkland Islands Government has already approved the transaction, the agreed long stop date has now expired, allowing either party to terminate the agreement. Despite this, both companies continue working to secure the remaining regulatory consent, leaving the timing and completion of Rockhopper’s exit from Italy uncertain.

Outlook

Rockhopper’s outlook remains constrained by inconsistent operating performance, characterised by minimal revenue generation and recurring operating losses. Technical indicators also remain weak, with the shares trading below key moving averages alongside negative MACD and subdued RSI and stochastic readings. Positive operating and free cash flow recorded during 2024 and 2025, together with a balance sheet supported by shareholder equity, provide some resilience, although higher leverage and volatile operating fundamentals continue to weigh on the investment case.

More about Rockhopper Exploration

Rockhopper Exploration plc is a UK-based oil and gas exploration and production company focused on the Falkland Islands. The group owns a 35% interest in licences within the North Falkland Basin, where development of the Sea Lion field, one of the region’s largest oil discoveries since its 2010 discovery, has been sanctioned. The company’s shares trade on AIM under the ticker RKH.

Kendrick Resources PLC (LSE:KEN) is advancing its southern African rare earth strategy through the Bonya Rare Earth Project in Namibia and the Blue Fox licence in Zambia, with the objective of progressing exploration assets into compliant mineral resources and, ultimately, production. The company’s focus is on supplying critical rare earth elements required by high-tech and industrial sectors.

Teufelskuppe drilling strengthens development outlook

Recent portable X-ray fluorescence (pXRF) results from diamond drilling at the Teufelskuppe rare earth project in Namibia have confirmed extensive high-grade mineralisation and strong continuity of light rare earth elements at depth. Several wide, high-grade intercepts place the carbonatite system among the highest-grade rare earth deposits globally, while work to establish a JORC 2012-compliant mineral resource is progressing. These results strengthen Teufelskuppe’s position as a potential near-term development project capable of becoming an important source of rare earth supply for free-market economies while reinforcing Namibia’s growing role in global critical minerals supply chains.

Exploration programme continues

Drilling activities remain ongoing as Kendrick expands the geological database required for its maiden formal mineral resource estimate. Early findings indicate that the existing 14-million-tonne surface resource could represent only a small portion of the project’s overall mineral potential. With demand for neodymium and praseodymium continuing to grow across permanent magnets, renewable energy systems, electric vehicles and defence applications, the size and grade of the Teufelskuppe rare earth system provide significant long-term development potential.

Outlook

Kendrick Resources continues to face financial challenges, with no revenue generation, ongoing losses, negative cash flow and a balance sheet weakened by negative equity. While technical indicators remain supportive, valuation metrics are difficult to assess because the company is loss-making and does not pay a dividend.

More about Kendrick Resources PLC

Kendrick Resources PLC is a mineral exploration and development company focused on acquiring and advancing rare earth and other mineral assets through exploration, technical evaluation and resource development. The company is progressing the Bonya Rare Earth Project in Namibia and the Blue Fox licence in northwest Zambia, with a strategy of bringing projects toward production through joint ventures, commercial partnerships or asset sales.

Its portfolio is centred on rare earth-bearing carbonatite systems, positioning the company to benefit from increasing demand for critical minerals used in advanced technology, renewable energy and defence industries. The Teufelskuppe project is emerging as a cornerstone asset, benefiting from established infrastructure and an in-house mineral resource currently being upgraded to JORC 2012 compliance.

Oxford BioDynamics (LSE:OBD) delivered modest revenue growth in its interim results, with revenue increasing to £0.69 million while the operating loss narrowed to £4.68 million. A £6.32 million equity fundraising strengthened the balance sheet, lifting period-end cash to £2.51 million. Despite these improvements, the board warned that additional funding will be required by late August 2026, even as demand for its U.S. prostate screening test continues to build.

Orion platform rollout gains momentum

The company recorded a sharp increase in Prostate Screening EpiSwitch (PSE) test volumes and expanded its media profile in the United States during the period. Oxford BioDynamics also introduced its cloud-based EpiSwitch Orion platform, which is already being used by leading research institutions and is under evaluation in discussions with three major pharmaceutical companies. To support commercial execution, the group appointed diagnostics industry veteran Richard Compton as chief executive officer, added a new non-executive director and engaged a third-party sales organisation. These initiatives are intended to accelerate adoption of Orion and additional products, including the ME/CFS blood test, while pursuing non-dilutive funding opportunities and enhancing shareholder value.

Outlook

Oxford BioDynamics continues to face financial headwinds despite improving commercial traction. Persistent losses, elevated leverage and deteriorating free cash flow remain significant challenges, while technical indicators suggest the shares remain in a downtrend, with only limited support from near-oversold momentum signals. Valuation also offers little encouragement, reflecting the company’s loss-making position and the absence of a dividend.

More about Oxford BioDynamics

Oxford BioDynamics is an AIM-listed biotechnology company specialising in precision diagnostic blood tests and its proprietary EpiSwitch 3D genomics platform. Its commercial offering includes the EpiSwitch Prostate Screening test and the Checkpoint Inhibitor Response Test, with operations spanning the UK, United States and Malaysia, alongside an expanding focus on pharmaceutical and biotechnology data partnerships.

The company’s cloud-based EpiSwitch Orion platform transforms standard and legacy sequencing datasets into actionable 3D genomic insights, enabling the analysis of non-coding disease variants that conventional genomics approaches often miss. Supported by an extensive disease-focused knowledge base, Oxford BioDynamics aims to advance drug target discovery, predictive biomarker development and precision medicine across oncology, neurology, inflammatory diseases and other therapeutic areas.

Shuka Minerals (LSE:SKA) used 2025 as a transformational year, implementing board changes, securing additional funding support and advancing its strategy to diversify beyond coal. Meanwhile, the company’s Rukwa coal mine in Tanzania remained under care and maintenance as preparations continued for a planned production restart in the third quarter of 2026. Management is progressing a targeted capital expenditure programme to bring the mine back online, with equipment leasing revenue providing interim support and negotiations continuing with cement and power sector customers for coal supply agreements covering up to 10,000 tonnes per month.

Kabwe acquisition broadens commodity portfolio

During the year, Shuka completed the acquisition of Leopard Exploration and Mining Limited, securing full ownership of the Kabwe Mine in Zambia. The historic lead and zinc operation holds independently verified mineral resources alongside favourable economic projections. Supported by a £2 million funding commitment from major shareholder Gathoni Muchai Investments, the appointment of new independent directors and a staged exploration and development programme, the company is expanding its exposure beyond coal while positioning itself for future growth across East and Central Africa.

Outlook

Shuka’s near-term outlook continues to be shaped by financial pressures and weak technical market signals. Although the Kabwe acquisition provides a potentially significant growth platform, delays in funding and unfavourable valuation metrics remain key factors weighing on investor sentiment.

More about Shuka Minerals Plc

Shuka Minerals Plc is an Africa-focused mining company listed on AIM in London and AltX in Johannesburg. Its portfolio includes the Rukwa coal mine in Tanzania and the recently acquired Kabwe lead-zinc-silver-vanadium project in Zambia, reflecting the company’s strategy of building a more diversified portfolio spanning coal and battery-related metals.

While policymakers kept rates unchanged at 3.5% -3.75%, nine of the 18 officials now expect a rate hike, as inflation projections were revised higher from 2.7% in March to 3.6% by the end of 2026, and to 2.3% for 2027 from 2.2%. 

Much of that deterioration came from events in the Middle East, especially disruptions in the Strait of Hormuz, which hit global energy supplies and pushed oil prices higher. Now that things seem to be easing, with shipping resuming and crude back below $75 a barrel, does that mean inflation could cool fast enough for the Fed to cut rates before year-end?

Not according to the CME FedWatch Tool, where the odds of rates being at 3.25%–3.50% by January 1st, 2027 are… 0%. 

And for good reason.

Although headline PCE inflation accelerated to 4.1% year-over-year in May, while core PCE remained elevated at 3.4% and broadly in line with expectations, both are still well above the Fed’s 2% target. Lower energy prices should eventually help, but policymakers know disinflation doesn’t happen overnight.

On top of that, the U.S. economy continues to hold up well. First-quarter GDP was revised higher to 2.1%, and the University of Michigan Consumer Sentiment Index rose to 49.5 in June from 44.8 in May. While confidence remains weak by historical standards, the direction of travel is positive.

Hence, the dollar (DXY) strengthened, while gold extended its decline.

Now all eyes are on this week’s labor market data. Payroll growth is expected to come in at around 115,000 jobs, down from 172,000 previously. If the numbers disappoint, markets could start pricing in a more dovish Fed. If, in turn, employment stays strong, rate-cut expectations will likely fade further. 

The European equity research landscape has welcomed a new entrant with the launch of European Equity Research Partners (EERP), an independent research house focused on delivering institutional-quality equity analysis on European-listed and Asian-listed companies.

At a time when research coverage for small and mid-cap companies across Europe remains limited, EERP aims to bridge an important gap by providing detailed company analysis, valuation frameworks and sector insights that can help investors better understand emerging growth opportunities.

The firm’s inaugural research note sets the tone for its analytical approach, initiating coverage on Spanish extended reality (XR) software specialist Virtualware (EU:ALVIR) with a BUY recommendation and a target price of €7.42 per share, representing approximately 33% upside from prevailing levels at the time of publication.

A Focus on Europe’s Undiscovered Growth Stories

The launch of EERP comes amid growing investor interest in under-researched European technology companies that possess strong intellectual property, scalable business models and international growth potential.

By choosing Virtualware as its first covered company, EERP has signalled an intention to focus on innovative businesses operating in attractive long-term growth markets. The report highlights Virtualware’s position within the rapidly expanding enterprise XR sector, where immersive training, industrial simulation and digital twin technologies are increasingly moving from experimental projects to mission-critical enterprise applications.

Why Virtualware Stood Out

According to EERP’s initiation report, Virtualware represents a compelling combination of technology leadership, improving financial performance and exposure to structural growth trends.

The report points to the company’s successful transformation from a bespoke project-based virtual reality developer into a scalable software platform business built around its flagship VIROO platform. This strategic shift has helped drive significantly higher margins while creating a more recurring and predictable revenue profile.

EERP also highlights the strategic importance of Virtualware’s acquisition of Simumatik, which strengthens the company’s capabilities in industrial simulation and digital twin environments. Together, the VIROO and Simumatik platforms position the business at the intersection of immersive training and industrial digitalisation, two areas expected to see substantial long-term investment from enterprises worldwide.

Confidence in the Growth Outlook

A key theme throughout the initiation note is EERP’s confidence in Virtualware’s ability to scale.

The research forecasts meaningful revenue growth over the coming years, supported by increasing adoption of subscription-based software products, expanding enterprise deployments and cross-selling opportunities arising from the integration of Simumatik. The report also notes that a significant proportion of management’s 2026 revenue guidance was already contracted early in the year, providing greater visibility than is often seen in companies of a similar size.

EERP argues that the market may not yet fully appreciate the operational leverage embedded within the business model. As software and platform revenues become a larger share of total sales, the company has the potential to deliver stronger profitability and cash generation over time.

Setting a Strong First Impression

For a newly launched research house, an inaugural note serves as an important statement of intent. EERP’s detailed initiation on Virtualware demonstrates a willingness to undertake deep fundamental analysis rather than simply follow larger, more widely covered companies.

The report combines sector analysis, business model assessment, financial forecasting and valuation work to present a comprehensive investment case. It also reflects a broader trend within European capital markets: the growing need for specialist research providers capable of shining a spotlight on innovative smaller companies that may otherwise remain overlooked by investors.

Looking Ahead

The debut of European Equity Research Partners represents a welcome addition to the European research ecosystem. By focusing on high-growth, under-covered opportunities such as Virtualware, the firm has the potential to become a valuable source of insight for investors seeking exposure to the next generation of European technology leaders.

If the quality and depth of its inaugural Virtualware report are any indication, EERP has launched with a clear ambition: to bring rigorous, independent analysis to companies whose growth stories deserve wider recognition across the investment community.

For more information on Virtualware visit https://virtualwareco.com